The critical role of Akt in cardiovascular function

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 38-48

  Abeyrathna, Prasanna ^a   Su, Yunchao ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Akt; Signal transduction; Vascular remodeling

Indexed keywords

BETA CATENIN; CARBOXY LTERMINAL MODULATOR PROTEIN; CASPASE 9; GLUCOSE TRANSPORTER 4; HEAT SHOCK PROTEIN 90; I KAPPA B KINASE EPSILON; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PLECKSTRIN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; PROTEIN YAP; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TANK BINDING KINASE 1; THREONINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR TCF4; TRB3 PROTEIN; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR ACK1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLOSTERISM; ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR FUNCTION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; VASCULAR REMODELING; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84947612492     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.05.008     Document Type: Review

References (186)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Bellacosa A., Franke T.F., Gonzalez-Portal M.E., Datta K., Taguchi T., Gardner J., et al. Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene 1993, 8:745-754.
3. Murthy S.S., Tosolini A., Taguchi T., Testa J.R. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet 2000, 88:38-40.
4. Franke T.F., Tartof K.D., Tsichlis P.N. The SH2-like Akt homology (AH) domain of c-akt is present in multiple copies in the genome of vertebrate and invertebrate eucaryotes. Cloning and characterization of the Drosophila melanogaster c-akt homolog Dakt1. Oncogene 1994, 9:141-148.
5. GeneCards V-akt murine thymoma viral oncogene homolog 1 http://www.genecards.org/cgi-bin/carddisp.pl?gene=AKT1#.
6. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
7. Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991, 254:274-277.
8. Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 1991, 88:4171-4175.
9. Coffer P.J., Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991, 201:475-481.
10. Bellacosa A., Testa J.R., Moore R., Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 2004, 3:268-275.
11. Laine J., Kunstle G., Obata T., Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem 2002, 277:3743-3751.
12. Cheng J.Q., Altomare D.A., Klein M.A., Lee W.C., Kruh G.D., Lissy N.A., et al. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 1997, 14:2793-2801.
13. Calera M.R., Pilch P.F. Induction of Akt-2 correlates with differentiation in Sol8 muscle cells. Biochem Biophys Res Commun 1998, 251:835-841.
14. Miwa W., Yasuda J., Murakami Y., Yashima K., Sugano K., Sekine T., et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996, 225:968-974.
15. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999, 274:21528-21532.
16. Dillon R.L., Muller W.J. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010, 70:4260-4264.
17. Shen Y.H., Zhang L., Ren P., Nguyen M.T., Zou S., Wu D., et al. AKT2 confers protection against aortic aneurysms and dissections. Circ Res 2013, 112:618-632.
18. Cho H., Thorvaldsen J.L., Chu Q., Feng F., Birnbaum M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001, 276:38349-38352.
19. Easton R.M., Cho H., Roovers K., Shineman D.W., Mizrahi M., Forman M.S., et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005, 25:1869-1878.
20. Phung T.L., Du W., Xue Q., Ayyaswamy S., Gerald D., Antonello Z., et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res 2015, 75:40-50.
21. Lee M.Y., Luciano A.K., Ackah E., Rodriguez-Vita J., Bancroft T.A., Eichmann A., et al. Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. Proc Natl Acad Sci U S A 2014, 111:12865-12870.
22. Morrow J.K., Du-Cuny L., Chen L., Meuillet E.J., Mash E.A., Powis G., et al. Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov 2011, 6:146-159.
23. Kumar C.C., Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005, 24:7493-7501.
24. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
25. Abid M.R., Guo S., Minami T., Spokes K.C., Ueki K., Skurk C., et al. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2004, 24:294-300.
26. Andjelkovic M., Jakubowicz T., Cron P., Ming X.F., Han J.W., Hemmings B.A. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 1996, 93:5699-5704.
27. Ushio-Fukai M., Alexander R.W., Akers M., Yin Q., Fujio Y., Walsh K., et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999, 274:22699-22704.
28. Takahashi T., Taniguchi T., Konishi H., Kikkawa U., Ishikawa Y., Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 1999, 276:H1927-H1934.
29. Dihlmann S., Kloor M., Fallsehr C., Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 2005, 26:1503-1512.
30. Park S., Kim D., Kaneko S., Szewczyk K.M., Nicosia S.V., Yu H., et al. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem 2005, 280:38932-38941.
31. Huls G., Koornstra J.J., Kleibeuker J.H. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003, 362:230-232.
32. Agarwal N.K., Qu C., Kunkalla K., Kunkulla K., Liu Y., Vega F. Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem 2013, 288:15390-15401.
33. Alessi D.R. Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem Soc Trans 2001, 29:1-14.
34. Vincent E.E., Elder D.J., Thomas E.C., Phillips L., Morgan C., Pawade J., et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 2011, 104:1755-1761.
35. Khor T.O., Gul Y.A., Ithnin H., Seow H.F. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett 2004, 210:139-150.
36. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008, 23:1-9.
37. Al-Saad S., Donnem T., Al-Shibli K., Persson M., Bremnes R.M., Busund L.T. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009, 29:4175-4183.
38. Peterson R.T., Schreiber S.L. Kinase phosphorylation: keeping it all in the family. Curr Biol 1999, 9:R521-R524.
39. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996, 15:6541-6551.
40. Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A., et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 2002, 9:1227-1240.
41. Frech M., Andjelkovic M., Ingley E., Reddy K.K., Falck J.R., Hemmings B.A. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 1997, 272:8474-8481.
42. James S.R., Downes C.P., Gigg R., Grove S.J., Holmes A.B., Alessi D.R. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J 1996, 315(Pt 3):709-713.
43. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997, 272:31515-31524.
44. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261-269.
45. Stokoe D., Stephens L.R., Copeland T., Gaffney P.R., Reese C.B., Painter G.F., et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277:567-570.
46. Hemmings B.A. PtdIns(3,4,5)P3 gets its message across. Science 1997, 277:534.
47. Wymann M.P., Zvelebil M., Laffargue M. Phosphoinositide 3-kinase signalling-which way to target?. Trends Pharmacol Sci 2003, 24:366-376.
48. Simpson L., Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001, 264:29-41.
49. Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P., Currie R., et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999, 9:393-404.
50. Williams M.R., Arthur J.S., Balendran A., van der Kaay J., Poli V., Cohen P., et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol 2000, 10:439-448.
51. Hill M.M., Andjelkovic M., Brazil D.P., Ferrari S., Fabbro D., Hemmings B.A. Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 2001, 276:25643-25646.
52. Moschella P.C., McKillop J., Pleasant D.L., Harston R.K., Balasubramanian S., Kuppuswamy D. mTOR complex 2 mediates Akt phosphorylation that requires PKCepsilon in adult cardiac muscle cells. Cell Signal 2013, 25:1904-1912.
53. Morton C.R., Du H.J., Xiao H.M., Maisch B., Zimmermann M. Inhibition of nociceptive responses of lumbar dorsal horn neurones by remote noxious afferent stimulation in the cat. Pain 1988, 34:75-83.
54. Chen R., Kim O., Yang J., Sato K., Eisenmann K.M., McCarthy J., et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001, 276:31858-31862.
55. Zheng Y., Peng M., Wang Z., Asara J.M., Tyner A.L. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 2010, 30:4280-4292.
56. Guo J.P., Coppola D., Cheng J.Q. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 2011, 286:37389-37398.
57. Joung S.M., Park Z.Y., Rani S., Takeuchi O., Akira S., Lee J.Y. Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol 2011, 186:499-507.
58. Bozulic L., Surucu B., Hynx D., Hemmings B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008, 30:203-213.
59. Peters R.T., Liao S.M., Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 2000, 5:513-522.
60. Tenoever B.R., Ng S.L., Chua M.A., McWhirter S.M., Garcia-Sastre A., Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278.
61. Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997, 278:866-869.
62. Cenni V., Sirri A., Riccio M., Lattanzi G., Santi S., de Pol A., et al. Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol Life Sci 2003, 60:2710-2720.
63. Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000, 97:10832-10837.
64. Wu R., Kausar H., Johnson P., Montoya-Durango D.E., Merchant M., Rane M.J. Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex. J Biol Chem 2007, 282:21598-21608.
65. Maira S.M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001, 294:374-380.
66. Du K., Herzig S., Kulkarni R.N., Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003, 300:1574-1577.
67. Alessi D.R., Caudwell F.B., Andjelkovic M., Hemmings B.A., Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996, 399:333-338.
68. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
69. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
70. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927.
71. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002, 277:21843-21850.
72. Gottlieb T.M., Leal J.F., Seger R., Taya Y., Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21:1299-1303.
73. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603.
74. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982.
75. Basu S., Totty N.F., Irwin M.S., Sudol M., Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003, 11:11-23.
76. Zhang X., Tang N., Hadden T.J., Rishi A.K. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011, 1813:1978-1986.
77. Barthwal M.K., Sathyanarayana P., Kundu C.N., Rana B., Pradeep A., Sharma C., et al. Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem 2003, 278:3897-3902.
78. Zhang R., Luo D., Miao R., Bai L., Ge Q., Sessa W.C., et al. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 2005, 24:3954-3963.
79. Sugishita Y., Leifer D.W., Agani F., Watanabe M., Fisher S.A. Hypoxia-responsive signaling regulates the apoptosis-dependent remodeling of the embryonic avian cardiac outflow tract. Dev Biol 2004, 273:285-296.
80. Cai S.L., Tee A.R., Short J.D., Bergeron J.M., Kim J., Shen J., et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006, 173:279-289.
81. Nascimento E.B., Snel M., Guigas B., van der Zon G.C., Kriek J., Maassen J.A., et al. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal 2010, 22:961-967.
82. Wang H., Zhang Q., Wen Q., Zheng Y., Lazarovici P., Jiang H., et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal 2012, 24:17-24.
83. Wiza C., Nascimento E.B., Ouwens D.M. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab 2012, 302:E1453-E1460.
84. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004, 24:6710-6718.
85. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.
86. Demirkan G., Yu K., Boylan J.M., Salomon A.R., Gruppuso P.A. Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1). PLoS One 2011, 6:e21729.
87. Zhu J., Blenis J., Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008, 105:6584-6589.
88. Amati B., Alevizopoulos K., Vlach J. Myc and the cell cycle. Front Biosci 1998, 3:d250-d268.
89. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
90. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001, 21:3995-4004.
91. Ackah E., Yu J., Zoellner S., Iwakiri Y., Skurk C., Shibata R., et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005, 115:2119-2127.
92. Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDaS6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A 1999, 96:4438-4442.
93. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277:38205-38211.
94. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
95. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006, 10:159-170.
96. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
97. Morales-Ruiz M., Fulton D., Sowa G., Languino L.R., Fujio Y., Walsh K., et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 2000, 86:892-896.
98. Dimmeler S., Dernbach E., Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000, 477:258-262.
99. Primo L., di Blasio L., Roca C., Droetto S., Piva R., Schaffhausen B., et al. Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 2007, 176:1035-1047.
100. Pitulescu M.E., Adams R.H. Eph/ephrin molecules-a hub for signaling and endocytosis. Genes Dev 2010, 24:2480-2492.
101. Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16:9-20.
102. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13:555-562.
103. Fujio Y., Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999, 274:16349-16354.
104. Papapetropoulos A., Fulton D., Mahboubi K., Kalb R.G., O'Connor D.S., Li F., et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000, 275:9102-9105.
105. Suhara T., Mano T., Oliveira B.E., Walsh K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 2001, 89:13-19.
106. Gratton J.P., Morales-Ruiz M., Kureishi Y., Fulton D., Walsh K., Sessa W.C. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 2001, 276:30359-30365.
107. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
108. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
109. Mai J., Qiu Q., Lin Y.Q., Luo N.S., Zhang H.F., Wen Z.Z., et al. Angiotensin II-derived reactive oxygen species promote angiogenesis in human late endothelial progenitor cells through heme oxygenase-1 via ERK1/2 and AKT/PI3K pathways. Inflammation 2014, 37:858-870.
110. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001, 98:2604-2609.
111. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
112. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem 2001, 276:32663-32669.
113. Brouet A., Sonveaux P., Dessy C., Moniotte S., Balligand J.L., Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001, 89:866-873.
114. Fontana J., Fulton D., Chen Y., Fairchild T.A., McCabe T.J., Fujita N., et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002, 90:866-873.
115. Luo Z., Fujio Y., Kureishi Y., Rudic R.D., Daumerie G., Fulton D., et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest 2000, 106:493-499.
116. Scotland R.S., Morales-Ruiz M., Chen Y., Yu J., Rudic R.D., Fulton D., et al. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res 2002, 90:904-910.
117. Iaccarino G., Ciccarelli M., Sorriento D., Cipolletta E., Cerullo V., Iovino G.L., et al. AKT participates in endothelial dysfunction in hypertension. Circulation 2004, 109:2587-2593.
118. Bae S.S., Cho H., Mu J., Birnbaum M.J. Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J Biol Chem 2003, 278:49530-49536.
119. Krycer J.R., Sharpe L.J., Luu W., Brown A.J. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 2010, 21:268-276.
120. Nakae J., Park B.C., Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999, 274:15982-15985.
121. Cross D.A., Alessi D.R., Vandenheede J.R., McDowell H.E., Hundal H.S., Cohen P. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 1994, 303(Pt 1):21-26.
122. Chavakis E., Dernbach E., Hermann C., Mondorf U.F., Zeiher A.M., Dimmeler S. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation 2001, 103:2102-2107.
123. Allard D., Figg N., Bennett M.R., Littlewood T.D. Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3. J Biol Chem 2008, 283:19739-19747.
124. Jia G., Cheng G., Gangahar D.M., Agrawal D.K. Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol Cell Biol 2006, 84:448-454.
125. Babaev V.R., Hebron K.E., Wiese C.B., Toth C.L., Ding L., Zhang Y., et al. Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. J Lipid Res 2014, 55:2296-2308.
126. Goetze S., Eilers F., Bungenstock A., Kintscher U. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002, 293:1431-1437.
127. Hardt S.E., Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 2004, 63:500-509.
128. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
129. Dorn G.W., Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005, 115:527-537.
130. Scheuer J., Malhotra A., Hirsch C., Capasso J., Schaible T.F. Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 1982, 70:1300-1305.
131. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975, 56:56-64.
132. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104:557-567.
133. Sano M., Schneider M.D. Still stressed out but doing fine: normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. Circulation 2002, 105:8-10.
134. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:12355-12360.
135. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004, 37:449-471.
136. Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004, 118:375-387.
137. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110:737-749.
138. Nagoshi T., Matsui T., Aoyama T., Leri A., Anversa P., Li L., et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 2005, 115:2128-2138.
139. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 2002, 99:12333-12338.
140. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118.
141. Cheng S.M., Ho T.J., Yang A.L., Chen I.J., Kao C.L., Wu F.N., et al. Exercise training enhances cardiac IGFI-R/PI3K/Akt and Bcl-2 family associated pro-survival pathways in streptozotocin-induced diabetic rats. Int J Cardiol 2013, 167:478-485.
142. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med 1994, 330:1431-1438.
143. Park K.W., Yang H.M., Youn S.W., Yang H.J. Constitutively Active Glycogen Synthase Kinase-3β Gene Transfer Sustains Apoptosis, Inhibits Proliferation of Vascular Smooth Muscle Cells, and Reduces Neointima 2003.
144. Gerber H.P., McMurtrey A., Kowalski J., Yan M. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. J Biol Chem 1998, 273:30336-30343.
145. Stabile E., Zhou Y.F., Saji M., Castagna M., Shou M., Kinnaird T.D., et al. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ Res 2003, 93:1059-1065.
146. Havelka G.E., Kibbe M.R. The vascular adventitia: its role in the arterial injury response. Vasc Endovascular Surg 2011, 45:381-390.
147. Garat C.V., Crossno J.T., Sullivan T.M., Reusch J.E., Klemm D.J. Inhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. J Cardiovasc Pharmacol 2013, 62:539-548.
148. Krymskaya V.P., Snow J., Cesarone G., Khavin I., Goncharov D.A., Lim P.N., et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011, 25:1922-1933.
149. Houssaini A., Abid S., Mouraret N., Wan F., Rideau D., Saker M., et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 2013, 48:568-577.
150. Goncharov D.A., Kudryashova T.V., Ziai H., Ihida-Stansbury K., DeLisser H., Krymskaya V.P., et al. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation 2014, 129:864-874.
151. Tang H., Chen J., Fraidenburg D.R., Song S., Sysol J.R., Drennan A.R., et al. Deficiency of Akt1, but not Akt2, attenuate the development of pulmonary hypertension. Am J Physiol Lung Cell Physiol 2015, 308:L208-L220.
152. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004, 3:763-772.
153. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241-5248.
154. Powis G., Bonjouklian R., Berggren M.M., Gallegos A., Abraham R., Ashendel C., et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994, 54:2419-2423.
155. Ikeda H., Hideshima T., Fulciniti M., Perrone G., Miura N., Yasui H., et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010, 116:1460-1468.
156. Bergamini G., Bell K., Shimamura S., Werner T., Cansfield A., Muller K., et al. A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat Chem Biol 2012, 8:576-582.
157. Straub A., Wendel H.P., Dietz K., Schiebold D., Peter K., Schoenwaelder S.M., et al. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost 2008, 99:609-615.
158. Lee H., Jung K.H., Jeong Y., Hong S., Hong S.S. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett 2013, 328:152-159.
159. Feldman R.I., Wu J.M., Polokoff M.A., Kochanny M.J., Dinter H., Zhu D., et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005, 280:19867-19874.
160. Meuillet E.J., Zuohe S., Lemos R., Ihle N., Kingston J., Watkins R., et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010, 9:706-717.
161. Sargeant A.M., Klein R.D., Rengel R.C., Clinton S.K., Kulp S.K., Kashida Y., et al. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 2007, 35:549-561.
162. Al-Batran S.E., Ducreux M., Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012, 130:491-496.
163. Zaytseva Y.Y., Valentino J.D., Gulhati P., Evers B.M. mTOR inhibitors in cancer therapy. Cancer Lett 2012, 319:1-7.
164. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
165. Garcia-Martinez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009, 421:29-42.
166. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010, 70:288-298.
167. Bonnet S., Rochefort G., Sutendra G. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007, 104:11418-11423.
168. Bonnet S., Paulin R., Sutendra G., Dromparis P., Roy M. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-β/NFAT axis. Circulation 2009, 120:1231-1240.
169. Munck J.M., Batey M.A., Zhao Y., Jenkins H., Richardson C.J., Cano C., et al. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol Cancer Ther 2012, 11:1789-1798.
170. Talekar M., Ganta S., Amiji M., Jamieson S., Kendall J., Denny W.A., et al. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. Int J Pharm 2013, 450:278-289.
171. Leahy J.J., Golding B.T., Griffin R.J., Hardcastle I.R., Richardson C., Rigoreau L., et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 2004, 14:6083-6087.
172. Yun J. Allosteric AKT, inhibitors as a targeted cancer therapy. Cancer Biol Ther 2010, 9:504-506.
173. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967.
174. Wilson J.M., Kunnimalaiyaan S., Gamblin T.C., Kunnimalaiyaan M. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. J Surg Res 2014, 191:280-285.
175. Luo Y., Smith R.A., Guan R., Liu X., Klinghofer V., Shen J., et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004, 43:1254-1263.
176. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003, 2:1093-1103.
177. Miao B., Skidan I., Yang J., Lugovskoy A., Reibarkh M., Long K., et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A 2010, 107:20126-20131.
178. Estrada A.C., Syrovets T., Pitterle K., Lunov O., Buchele B., Schimana-Pfeifer J., et al. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387.
179. Lochner A., Moolman J.A. The many faces of H89: a review. Cardiovasc Drug Rev 2006, 24:261-274.
180. Heerding D.A., Rhodes N., Leber J.D., Clark T.J., Keenan R.M., Lafrance L.V., et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H- imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem 2008, 51:5663-5679.
181. Yap T.A., Walton M.I., Hunter L.J., Valenti M., de Haven Brandon A., Eve P.D., et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther 2011, 10:360-371.
182. Mosca E., Barcella M., Alfieri R., Bevilacqua A., Canti G., Milanesi L. Systems biology of the metabolic network regulated by the Akt pathway. Biotechnol Adv 2012, 30:131-141.
183. Brown D.J., Rzucidlo E.M., Merenick B.L., Wagner R.J., Martin K.A., Powell R.J. Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. J Vasc Surg 2005, 41:509-516.
184. Yang C., Li X., Wang Y., Zhao L., Chen W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 2012, 496:8-16.
185. Tsang D.P., Cheng A.S. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011, 26:19-27.
186. Zuo T., Liu T.M., Lan X., Weng Y.I., Shen R., Gu F., et al. Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res 2011, 71:1752-1762.